U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 20

1.

Copy number analysis of OVCAR-3 and CDK2 resistant sublines

(Submitter supplied) Cyclin E1 (CCNE1) is amplified in various tumor types including high-grade serous ovarian cancer where it is associated with poor clinical outcome. We have demonstrate that suppression of the Cyclin E1 partner kinase, CDK2, induces apoptosis in a CCNE1 amplicon-dependent manner. Little is known of mechanisms of resistance to CDK inhibitors. We therefore generated OVCAR-3 sublines with reduced sensitivity to CDK2 inhibitors and profiled by SNP copy number microarrays.
Organism:
Homo sapiens
Type:
Genome variation profiling by SNP array
Platform:
GPL13135
6 Samples
Download data: TXT
Series
Accession:
GSE48920
ID:
200048920
2.

Gene expression and copy number analysis of OVCAR-3 and CDK2 resistant sublines

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Genome variation profiling by SNP array; Expression profiling by array
Platforms:
GPL6244 GPL13135
20 Samples
Download data: CEL, TXT
Series
Accession:
GSE48921
ID:
200048921
3.

Gene expression analysis of OVCAR-3 and CDK2 resistant sublines

(Submitter supplied) Cyclin E1 (CCNE1) is amplified in various tumor types including high-grade serous ovarian cancer where it is associated with poor clinical outcome. We have demonstrate that suppression of the Cyclin E1 partner kinase, CDK2, induces apoptosis in a CCNE1 amplicon-dependent manner. Little is known of mechanisms of resistance to CDK inhibitors. We therefore generated OVCAR-3 sublines with reduced sensitivity to CDK2 inhibitors and profiled by gene expression microarrays.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6244
14 Samples
Download data: CEL
Series
Accession:
GSE48919
ID:
200048919
4.

Expression data from primary breast tumors (Auckland)

(Submitter supplied) Frozen tissue specimens from primary breast tumors were collected and profiled using Affymetrix U133 plus 2 expression microarrays. A publication describing the generation of these data is not yet available. However, these data can be used alongside other Affymetrix breast tumour data sets to form large meta-cohorts for breast cancer research, as was done in Lasham et. al. J Natl Cancer Inst. 2012 Jan 18;104(2):133-146.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
107 Samples
Download data: CEL
Series
Accession:
GSE36771
ID:
200036771
5.

Characterization of murine hepatoma cells with regard to their dependence on cyclin E1

(Submitter supplied) In C57BL/6 mice with a floxed cyclin E1 (CcnE1) gene (CcnE1f/f), hepatocellular carcinomas were induced using diethylnitrosamine (DEN). Hepatocyte-derived cells from pre-cancerous but tumor-free liver tissue (referred to as CcnE1f/fpreCL) and from large, solid HCC nodules (referred to as CcnE1f/fHCC) were isolated and immortalized in vitro. Deletion of CcnE1 in CcnE1f/fpreCL cells resulted in cell cycle arrest and death while CcnE1f/fHCC cells grew almost normal after loss of CcnE1. more...
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL19057
17 Samples
Download data: XLSX
Series
Accession:
GSE111079
ID:
200111079
6.

50K SNP Copy Number Analysis of Ovarian Carcinomas

(Submitter supplied) Genome-wide copy number variation was measured in primary tumours of the ovary, Fallopian tube and peritoneum. A well-defined subset of advanced-stage serous tumors was then used to relate CNV to primary resistance to treatment. Analysis is described in: Etemadmoghadam, D., et al. (2009). "Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas." Clin Cancer Res 15(4): 1417-27.
Organism:
Homo sapiens
Type:
Genome variation profiling by SNP array
Platform:
GPL2005
118 Samples
Download data: CEL, TXT
Series
Accession:
GSE13813
ID:
200013813
7.

Comparison of parental and CDKi-resistant ovarian cancer cell lines

(Submitter supplied) High-grade serous ovarian cancers (HGSOC) are genomically complex, heterogeneous cancers with a high mortality rate, due to acquired chemoresistance and lack of targeted therapy options. Cyclin-dependent kinase inhibitors (CDKi) target the retinoblastoma (RB) signaling network, and have been successfully incorporated into treatment regimens for breast and other cancers. Here, we have compared mechanisms of response and resistance to three CDKi that target either CDK4/6 or CDK2 and abrogate E2F target gene expression. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL10558
34 Samples
Download data: IDAT, TXT
Series
Accession:
GSE63529
ID:
200063529
8.

CCNE1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice

(Submitter supplied) Background & Aims: The CCNE1 locus, which encodes cyclin E1, is amplified in many types of cancer cells and is activated in hepatocellular carcinomas (HCCs) from patients infected with hepatitis B virus or adeno-associated virus type 2, due to integration of the virus nearby. We investigated cell cycle and oncogenic effects of cyclin E1 overexpression in tissues of mice. Methods: We generated mice with doxycycline-inducible expression of Ccne1 (Ccne1T mice) and activated overexpression of cyclin E1 from age 3 weeks onwards. more...
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL21103
18 Samples
Download data: TXT
Series
Accession:
GSE126445
ID:
200126445
9.

Affymetrix SNP array data for ovarian cancer cells OVCAR-3 and FU-OV-1

(Submitter supplied) A subset of ovarian cancer are characterized by 19q12 amplification. To perform funtional studies of this amplicon the profile has been determined by SNP analysis.
Organism:
Homo sapiens
Type:
Genome variation profiling by SNP array; SNP genotyping by SNP array
Platform:
GPL6801
2 Samples
Download data: CEL, CNCHP
Series
Accession:
GSE26301
ID:
200026301
10.

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens; Mus musculus
Type:
Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing
Platforms:
GPL18573 GPL19057
130 Samples
Download data: BW
Series
Accession:
GSE243154
ID:
200243154
11.

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [Gastric mouse (GA0103) RNAseq]

(Submitter supplied) We performed RNA sequencing on tumours harvested from GA0103 (gastric cancer) PDX treated for 40-50 days with either control vehicle or 100 mg/kg BID INX-315.
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL19057
8 Samples
Download data: CSV
Series
Accession:
GSE243153
ID:
200243153
12.

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OVCAR3 RNAseq]

(Submitter supplied) We performed RNA sequencing on OVCAR3 parental cells treated with either control vehicle for 4 days or 300 nM INX-315 for 7 days.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL18573
6 Samples
Download data: CSV
Series
Accession:
GSE243152
ID:
200243152
13.

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OV5398PDX RNAseq]

(Submitter supplied) We performed RNA sequencing on tumors harvested from OV5398 (ovarian) PDX treated for 40-50 days with either control vehicle (PEG), 100 mg/kg BID INX-315 or 200 mg/kg QD INX315.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL18573
11 Samples
Download data: CSV
Series
Accession:
GSE243151
ID:
200243151
14.

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [MCF7 and T47D RNAseq]

(Submitter supplied) We performed RNA sequencing on T47D and MCF7 cells, both parental and abema- or abema/fulvestrant- resistant, treated with either control vehicle or 300 nM (MCF7) or 100 nM (T47D) INX-315 for 7 days
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL18573
48 Samples
Download data: CSV
Series
Accession:
GSE243150
ID:
200243150
15.

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [HER2mouse upfront RNAseq]

(Submitter supplied) We treated tumour-bearing MMTV-rtTA/tetO-HER2 female mice with either vehicle (veh), INX-315 (INX), Abemaciclib (LY) or both INX-315 and Abema in combination (LY.INX) for 7 days. Resistant tumors were collected and RNA sequencing performed
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL19057
19 Samples
Download data: CSV
Series
Accession:
GSE243149
ID:
200243149
16.

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [HER2mouse resistant RNAseq]

(Submitter supplied) We treated tumour-bearing MMTV-rtTA/tetO-HER2 female mice with 75 mg/kg Abemaciclib for ~4 weeks (or until point of resistance, where tumours have started to grow again). Mice were then divided into treatment groups, receiving vehicle (veh), INX-315 (INX), Abemaciclib (LY) or both INX-315 and Abema in combination (LY.INX). Resistant tumors were collected and RNA sequencing performed.
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL19057
22 Samples
Download data: CSV
Series
Accession:
GSE243148
ID:
200243148
17.

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [MCF7 ATACseq]

(Submitter supplied) We performed the Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-Seq) on (i) parental MCF7 cells treated with control vehicle or abemaciclib (ii) abemaciclib- and abemaciclib/fulvestrant-resistant cells treated with control vehicle or INX-315.
Organism:
Homo sapiens
Type:
Genome binding/occupancy profiling by high throughput sequencing
Platform:
GPL18573
16 Samples
Download data: BW, NARROWPEAK
Series
Accession:
GSE243147
ID:
200243147
18.

Transcriptional profilng of CCNE1 overexpressing hTERT-immortalized p53-R175H fallopian tube cell lines (FT282)

(Submitter supplied) In this study we used RNA-seq to profile transcriptional changes in two clones of FT282-hTERT p53-R175H cells engineered to overexpress CCNE1. We compared the differential gene expression (DGE) of CCNE1 OE to their wild type counterparts and identified that CCNE1 OE increases expression of genes involved in G2/M progression. Subsequent gene set enrichment analysis (GSEA) revealed significant enrichment of genes co-regulated by MYBL2 and FOXM1 transcription factors.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL24676
9 Samples
Download data: XLSX
19.

Whole genome characterisation of chemoresistant ovarian cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below. Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. more...
Organism:
Homo sapiens
Type:
Non-coding RNA profiling by array; Methylation profiling by genome tiling array; Genome variation profiling by SNP array
4 related Platforms
356 Samples
Download data: CSV, IDAT, TXT
Series
Accession:
GSE65821
ID:
200065821
20.

Whole genome characterisation of chemoresistant ovarian cancer [Illumina_450K_Methylation]

(Submitter supplied) Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. more...
Organism:
Homo sapiens
Type:
Methylation profiling by genome tiling array
Platform:
GPL13534
121 Samples
Download data: IDAT
Series
Accession:
GSE65820
ID:
200065820
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=3|blobid=MCID_67345039083b6455f34a2527|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center